PTC Therapeutics(CH:P91)
CH:P91
PTC Therapeutics ownership
PTC Therapeutics (P91) Ownership - Who Owns PTC Therapeutics?
1 Followers
PTC Therapeutics (P91) Ownership Overview
- 3.02% Insiders
- 30.34% Mutual Funds
- 28.49% Other Institutional Investors
- 29.06% ETFs
- 9.08% Public Companies and Individual Investors
The ownership structure of PTC Therapeutics (CH:P91) stock is a mix of institutional, retail, and individual investors. Approximately 87.90% of the company’s stock is owned by Institutional Investors, 3.02% is owned by Insiders, and 9.08% is owned by Public Companies and Individual Investors.
Institutional holdings as of (latest 13F reporting period).
The ownership structure of PTC Therapeutics (CH:P91) stock is a mix of institutional, retail, and individual investors. Approximately 87.90% of the company’s stock is owned by Institutional Investors, 3.02% is owned by Insiders, and 9.08% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| May 14, 2026 | Matthew B. Klein | $917,154 | |
| Apr 22, 2026 | Matthew B. Klein | $202,094 | |
| Apr 05, 2026 | Lee Scott Golden | $56,364 | |
| Mar 12, 2026 | Matthew B. Klein | $170,581 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2025 | Manning & Napier Advisors Llc | CHF9,495 | |
| Dec 31, 2025 | Bridgewater Associates, Lp | CHF1,232,754 | |
| Dec 31, 2025 | Hussman Strategic Advisors Inc | CHF1,914,192 | |
| Dec 31, 2025 | Royce & Associates Llc | CHF6,137,112 |
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| BlackRock, Inc. | 14,397,317 | Institution | 17.23% | ― |
| Ishares | 10,274,419 | Institution | 12.30% | ― |
| Vanguard | 7,017,913 | Institution | 8.40% | ― |
| Vanguard Index Funds | 6,586,978 | Institution | 7.88% | ― |
| Spdr | 3,851,189 | Institution | 4.61% | ― |
| Vanguard Specialized Funds | 2,310,268 | Institution | 2.77% | ― |
| Janus Investment Fund | 1,901,852 | Institution | 2.28% | ― |
| Michael Schmertzler | 1,454,860 | Insider | 1.74% | ― |
| Steve Weber | 1,236,579 | Institution | 1.48% | ― |
| Fidelity Salem Street Trust | 1,000,852 | Institution | 1.20% | ― |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard Index Funds | 6,586,978 | Institution | 7.88% | ― |
| Vanguard Specialized Funds | 2,310,268 | Institution | 2.77% | ― |
| Janus Investment Fund | 1,901,852 | Institution | 2.28% | ― |
| Fidelity Salem Street Trust | 1,000,852 | Institution | 1.20% | ― |
| Fidelity Concord Street Trust | 914,427 | Institution | 1.09% | ― |
| Manager Directed Portfolios | 832,255 | Institution | 1.00% | ― |
| Capitol Series Trust | 780,300 | Institution | 0.93% | ― |
| Tiaa-cref Funds | 680,537 | Institution | 0.81% | ― |
| Bridge Builder Trust | 576,436 | Institution | 0.69% | ― |
| Vanguard Scottsdale Funds | 570,699 | Institution | 0.68% | ― |
FAQ
Who Owns PTC Therapeutics (CH:P91)?
According to the latest TipRanks data (13F holdings as of December 31, 2025), approximately 87.90% of the company's stock is held by institutional investors, 3.02% is held by insiders, and 9.08% is held by public companies and individual investors.
What percentage of PTC Therapeutics (CH:P91) stock is held by institutional investors?
According to the latest TipRanks data (13F holdings as of December 31, 2025), approximately 87.90% of PTC Therapeutics (CH:P91) stock is held by institutional investors: 30.34% by mutual funds, 29.06% by ETFs and 28.49% by other institutional investors.
What percentage of PTC Therapeutics (CH:P91) stock is held by retail investors?
According to the latest TipRanks data (13F holdings as of December 31, 2025), approximately 9.08% of PTC Therapeutics (CH:P91) stock is held by public companies and individual investors.
Who owns the most shares of PTC Therapeutics (CH:P91)?
BlackRock, Inc. owns the most shares of PTC Therapeutics (CH:P91).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.

